SPY769.35QQQ743.79+0.36%BTC/USD83,842.02−0.64%DIA514.20+0.30%GLD392.60+0.23%TLT79.40−0.03%
Benzinga

Monte Rosa Therapeutics Inc (GLUE) Stock Price, Quote, News & History

GLUENASDAQ
Trade with Public
Trade with Public
$11.80
0.080.68%
Last update: Sep 25, 8:34 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Monte Rosa Therapeutics (GLUE) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$11.75
Close
-
Volume / Avg.
25.64K / 1.42M
Day Range
$11.69 - $11.84
52 Wk Range
6.37 - 25.77
Market Cap
$1.01B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
28
Short Interest
21.52%
Days to Cover
17.08

Recent Monte Rosa Therapeutics, Inc. News

Crude Oil Down 2%; ISM Services PMI Surges In December

Avi Kapoor

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and reduction in inflammatory markers.
Vandana Singh

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Why Is Monte Rosa Stock Trading Higher Today?

Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
Vandana Singh

Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-24.07M
Investing Cash Flow (TTM)
-316.79M
Financing Cash Flow (TTM)
361.52M
Free Cash Flow (TTM)
-32.08M
Capital Expenditure (TTM)
-8.01M
Net Change in Cash (TTM)
20.66M

Analyst Trends and Forecast

1
May
1
Jun
5
Aug
1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$418.04M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
37.72
PB Ratio (TTM)
2.05
Earnings Yield % (TTM)
-14.91%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$5.71

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$90.10M
Debt to Equity
0.08
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$11.75
Close
-
Volume / Avg.
25.64K / 1.42M
Day Range
$11.69 - $11.84
52 Wk Range
6.37 - 25.77
Market Cap
$1.01B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
28
Short Interest
21.52%
Days to Cover
17.08

About

Sector
Health Care
Industry
Biotechnology
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degra...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Monte Rosa Therapeutics (GLUE) stock?

A

You can purchase shares of Monte Rosa Therapeutics (NASDAQ:GLUE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Monte Rosa Therapeutics (GLUE) competitors?

Q

What is the forecast, or price target, for Monte Rosa Therapeutics (GLUE) stock?

A

Monte Rosa Therapeutics has a consensus price target of $25.14.

Q

What is the current price for Monte Rosa Therapeutics (GLUE)?

A

The stock price for Monte Rosa Therapeutics (NASDAQ: GLUE) is $11.8 last updated September 25, 2026 at 8:34 AM EDT.

Q

Does Monte Rosa Therapeutics (GLUE) pay a dividend?

A

There are no upcoming dividends for Monte Rosa Therapeutics.

Q

When is Monte Rosa Therapeutics (NASDAQ:GLUE) reporting earnings?

A

Monte Rosa Therapeutics does not have any upcoming earnings scheduled.

Q

Is Monte Rosa Therapeutics (GLUE) going to split?

A

There is no upcoming split for Monte Rosa Therapeutics.

Q

What sector and industry does Monte Rosa Therapeutics (GLUE) operate in?

A

Monte Rosa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved